EGFR and non-small cell lung carcinoma: To gain insights into the mechanism responsible for the lack of additive effects of sorafenib and osimertinib in NSCLC cells, we investigated how these compounds, alone or in combination, affect MCL1, eIF4E, and EGFR in osimertinib-sensitive and resistant cells.